Eupraxia's DiffuSphere? Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months
VICTORIA, BC, Nov. 20, 2024 -?Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ: EPRX) (TSX: EPRX), a clinical-stage biotechnology company, today unveiled new pharmacokinetic ("PK") data from its Phase 2a Eosinophilic Esophagitis ("EoE") program. Management believes these data underscore the unique capabilities of Eupraxia's proprietary DiffuSphere? platform technology, which aims to provide precise, localized, safe, and effective long-lasting drug delivery.
View the entire press release here: